PIK3CA and lung carcinoma: (48) successfully developed a panel of seven autoantibodies (reactive with: TP53, NPM1, FGFR2, PIK3CA, GNA11, HIST1H3B, and TSC1) for effective early detection of lung cancer, as well as providing novel targets for lung cancer immunotherapy.